<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657875</url>
  </required_header>
  <id_info>
    <org_study_id>D1843R00280</org_study_id>
    <nct_id>NCT03657875</nct_id>
  </id_info>
  <brief_title>Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network (HEKATE)</brief_title>
  <official_title>Retrospective Study to Describe Prevalence of Hyperkalemia in Russian Population Based on Large Laboratory Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is a cross-sectional retrospective study of laboratory records of patients who take
      electrolytes blood tests containing the data of the serum potassium level. This study is an
      observational one, and there is no intervention into routine clinical practice either in
      terms of therapy, or special examinations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2017</start_date>
  <completion_date type="Actual">September 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 15, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of the individuals with the serum potassium level higher than 5.0, 5.5, and 6.0 mmol/L</measure>
    <time_frame>One day</time_frame>
    <description>To determine the proportion of the individuals with the serum potassium level higher than 5.0, 5.5, and 6.0 mmol/L based on INVITRO laboratory database during 2015-2016 years.</description>
  </primary_outcome>
  <enrollment type="Actual">53940</enrollment>
  <condition>Hyperkalemia Elevated Plasma K+ Cardiovascular Disease (CVD)</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Data collection will be performed from anonymous available database of Independent Laboratory
      INVITRO.

      For the proper calculation of prevalence proportions and proper assessment of associations,
      the following method of the selection of tests results for corresponding statistical analysis
      will be applied:

        -  For the analysis of primary endpoint, first available result (chronologically) will
           always be selected for potassium

        -  For the analysis of all secondary endpoints and associations between potassium levels
           and levels of sodium (Na), eGFR, urine albumin, HbA1C, and NT-proBNP or BNP,
           chronologically matching results will be selected for potassium and other corresponding
           parameter, in this case, first available result (chronologically) will be selected for
           the parameter of interest (i.e. sodium, creatinine (for eGFR), urine albumin, HbA1C, and
           NT-proBNP or BNP) and matching result (of the same date or Â±1 day) for potassium will be
           selected

        -  If any first available result is unreliable o
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in Russia 18 years and older whose blood samples were analysed in the independent
        laboratory INVITRO for serum potassium level (K), from 01.01.2015 till 31.12.2016.

        From the main dataset with serum potassium level, subgroups will be selected with available
        serum sodium (Na), creatinine (for calculation of eGFR with CKD-EPI formula), urine
        albumin, HbA1C, and NT-proBNP or BNP.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females tested in the Russian centres of INVITRO laboratory from 01.01.2015
             till 31.12.2016;

          -  18 years and older;

          -  Available electrolytes blood test containing of the serum potassium level of the
             unique patient fits for interpretation.

        Exclusion Criteria:

          -  Blood test cannot be interpreted due to various reasons.

          -  Blood samples with sing of hemolysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Invitro</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

